Norvatis

Novartis India’s board approved the transaction before the company signed an asset purchase agreement and trademark assignment deeds with Pfizer and Pfizer Products.

The partnership expands the use of ALT B4, a proprietary recombinant human hyaluronidase developed through Alteogen’s Hybrozyme platform.

Under the four-year agreement, Novartis India had granted Dr Reddy’s an exclusive and non-transferable right to promote, distribute and sell certain products in the Indian market.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

Antares will lead the research phase and apply its proprietary drug-discovery platform to a limited number of oncology targets before Novartis decides whether to exercise licensing options for individual programmes.

The acquisition signals Novartis’s confidence that Exl-111 can outperform this proven therapy by taking an entirely different approach.

Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.

The acquisition involves Novartis purchasing Pikavation Therapeutics, a wholly owned subsidiary of Synnovation Therapeutics that holds the rights to SNV4818 and related research programs.

The expansion of Cosentyx to this population addresses a critical gap in care and demonstrates Novartis’ focus on advancing solutions where the company can make the greatest impact on patient outcomes.